MiCheck Archives - We are Minomic

New Peer-Reviewed Paper on MiCheck^® Prostate

by Minomic | Oct 5, 2023

Minomic is pleased to announce the publication of the company’s latest research paper supporting the utilisation of MiCheck® Prostate as an aid to diagnosing clinically significant prostate cancer. It is clear there is strong clinical need to identify those patients...

Dr Brad Walsh’s interview on Australia’s leading business and finance streaming service AusBiz

by Minomic | Oct 3, 2023

Last Thursday Dr Brad Walsh was interviewed on Australia’s leading business and finance streaming service, AusBiz by renowned TV personality David Koch about Minomic’s technology and future plans as a fitting end to Prostate Cancer Awareness Month. You can view...

Minomic International Ltd Receives Reimbursement for MiCheck^® Prostate in the USA

by Minomic | Sep 28, 2023

Thursday 28 September, Sydney, Australia Sydney-based biotech Minomic International Ltd is delighted to announce that the company’s ground-breaking test for prostate cancer, MiCheck® Prostate, has received its first reimbursement in the United States from the Centres...

Minomic’s presentation at the 23rd Asia-Paciﬁc Prostate Cancer Conference

by Minomic | Aug 18, 2023

We are proud to be presenting at the 23rd Asia-Paciﬁc Prostate Cancer Conference, one of the largest comprehensive prostate cancer meetings in the world, that is being held between 18 – 20 August 2023 in Cairns. Minomic CEO, Dr Brad Walsh will present a poster...

PUBLICATIONS

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis. Sayyadi, N, Justiniano, I, Wang, Y, Zheng, X, Zhang, W, Jiang, L, Polikarpov, DM, Willows, RD, Gillatt, D, Campbell, D, Walsh, BJ, Yuan, J, Lu, Y, Packer, NH, Wang, Y & Piper, JA 2022. Scientific Reports, vol. 12, no. 1, 18452.

Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. Zhang, W, Campbell, DH, Walsh, BJ, Packer, NH, Liu, D & Wang, Y 2022. Journal of Nanobiotechnology, vol. 20, no. 1, 446.

Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study. Wei Zhang, Ling Wang, Dan Li, Douglas H. Campbell, Bradley J. Walsh, et al. RSC. 2022.

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate

New Peer-Reviewed Paper on MiCheck® Prostate